Tags

Type your tag names separated by a space and hit enter

Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Colloids Surf B Biointerfaces. 2017 Jun 01; 154:321-330.CS

Abstract

Current treatment therapeutic approach for tuberculosis is the administration of first line drugs in the form of tablets and capsules for 4-6 months. However, this approach leads to severe adverse effects. Therefore, present study was designed to achieving local and sustained targeting of anti-tubercular drugs in order to reduce dose and frequency. The nanoparticle based dry powder formulation of rifampicin was developed and analyzed with respect to its direct targeting potential of lungs. Rifampicin loaded nanoparticles were formulated by ionic gelation probe sonication method, and characterized with respect to particle size, zeta potential, entrapment and drug loading efficiency. The range of size and entrapment efficiency of prepared nanoparticles was estimated from 124.1±0.2 to 402.3±2.8nm and 72.00±0.1%, respectively. The freeze-dried powder of nanoparticle formulation was used to carry out in vitro lung deposition studies through Andersen cascade impactor. The cumulative in vitro drug release studies with developed nanoparticle formulation showed sustained release up to 24h. Our in vitro sustained drug release results were corroborated by the extended residence and slow clearance of rifampicin from the lungs. Furthermore, our results suggest the minimum lung distribution of drug in treated rats which confirms the negligible toxicity rendered by nanoparticle dry powder formulation. Moreover, pharmacokinetic and toxicity studies carried out with prepared NPs dry powder inhalation (DPI) formulations and compared with conventional DPI.

Authors+Show Affiliations

Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India.Institute of Science, Nirma University, Ahmedabad 382481, Gujarat, India.Institute of Science, Nirma University, Ahmedabad 382481, Gujarat, India.Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India. Electronic address: shital_26@yahoo.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28363192

Citation

Rawal, Tejal, et al. "Rifampicin Loaded Chitosan Nanoparticle Dry Powder Presents an Improved Therapeutic Approach for Alveolar Tuberculosis." Colloids and Surfaces. B, Biointerfaces, vol. 154, 2017, pp. 321-330.
Rawal T, Parmar R, Tyagi RK, et al. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. Colloids Surf B Biointerfaces. 2017;154:321-330.
Rawal, T., Parmar, R., Tyagi, R. K., & Butani, S. (2017). Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. Colloids and Surfaces. B, Biointerfaces, 154, 321-330. https://doi.org/10.1016/j.colsurfb.2017.03.044
Rawal T, et al. Rifampicin Loaded Chitosan Nanoparticle Dry Powder Presents an Improved Therapeutic Approach for Alveolar Tuberculosis. Colloids Surf B Biointerfaces. 2017 Jun 1;154:321-330. PubMed PMID: 28363192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. AU - Rawal,Tejal, AU - Parmar,Rajesh, AU - Tyagi,Rajeev K, AU - Butani,Shital, Y1 - 2017/03/21/ PY - 2016/12/26/received PY - 2017/02/21/revised PY - 2017/03/20/accepted PY - 2017/4/1/pubmed PY - 2018/2/27/medline PY - 2017/4/1/entrez KW - Chitosan KW - Dry powder KW - Freeze drying KW - Nanoparticles KW - Pulmonary KW - Rifampicin SP - 321 EP - 330 JF - Colloids and surfaces. B, Biointerfaces JO - Colloids Surf B Biointerfaces VL - 154 N2 - Current treatment therapeutic approach for tuberculosis is the administration of first line drugs in the form of tablets and capsules for 4-6 months. However, this approach leads to severe adverse effects. Therefore, present study was designed to achieving local and sustained targeting of anti-tubercular drugs in order to reduce dose and frequency. The nanoparticle based dry powder formulation of rifampicin was developed and analyzed with respect to its direct targeting potential of lungs. Rifampicin loaded nanoparticles were formulated by ionic gelation probe sonication method, and characterized with respect to particle size, zeta potential, entrapment and drug loading efficiency. The range of size and entrapment efficiency of prepared nanoparticles was estimated from 124.1±0.2 to 402.3±2.8nm and 72.00±0.1%, respectively. The freeze-dried powder of nanoparticle formulation was used to carry out in vitro lung deposition studies through Andersen cascade impactor. The cumulative in vitro drug release studies with developed nanoparticle formulation showed sustained release up to 24h. Our in vitro sustained drug release results were corroborated by the extended residence and slow clearance of rifampicin from the lungs. Furthermore, our results suggest the minimum lung distribution of drug in treated rats which confirms the negligible toxicity rendered by nanoparticle dry powder formulation. Moreover, pharmacokinetic and toxicity studies carried out with prepared NPs dry powder inhalation (DPI) formulations and compared with conventional DPI. SN - 1873-4367 UR - https://www.unboundmedicine.com/medline/citation/28363192/Rifampicin_loaded_chitosan_nanoparticle_dry_powder_presents_an_improved_therapeutic_approach_for_alveolar_tuberculosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0927-7765(17)30162-5 DB - PRIME DP - Unbound Medicine ER -